An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
June 16th 2021, 9:00pm
The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.
June 10th 2021, 1:00pm
Treatment with this combination was associated with encouraging clinical responses in this patient population.
June 8th 2021, 4:00pm
Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.
June 7th 2021, 9:00pm
Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
April 28th 2021, 12:30pm
Don’t let your disease define you
April 23rd 2021, 9:00pm
Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.
April 22nd 2021, 9:00pm
Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.
April 16th 2021, 12:00pm
Navigating life with blood cancer
March 17th 2021, 12:00pm
March 3rd 2021, 7:00pm
Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.
Adding Darzalex to Standard of Care May Improve Survival in Newly Diagnosed Multiple Myeloma
A ‘Turning Point’ for Metastatic NSCLC Treatment
My Daughter, the Learning Opportunity
Expert Breaks Down Misconceptions About COVID-19 Vaccine
